19. The chemical compound of claim 18, wherein the linker is a substituted carbon chain incorporating a secondary or tertiary amine.

 $\mathcal{B}'$ 

- 20. The chemical compound of claim 19, wherein the linker is an N-methylamino linker.
- 21. The chemical compound of claim 18, wherein the linker is a substituted carbon chain incorporating an aryl group.
- 22. The chemical compound of claim 3, wherein the linker is a substituted carbon chain.
- 23. The chemical compound of claim 22, wherein the linker is a substituted carbon chain incorporating a secondary or tertiary amine.
- 24. The chemical compound of claim 23, wherein the linker is an N-methylamino linker.
- 25. The chemical compound of claim 22, wherein the linker is a substituted carbon chain incorporating an aryl group.
  - 26. The method of claim 12, wherein the linker is a substituted carbon chain.
- 27. The method of claim 26, wherein the linker is a substituted carbon chain incorporating a secondary or tertiary amine.
  - 28. The method of claim 27, wherein the linker is an N-methylamino linker.

- 29. The method of claim 27, wherein the first and second hsp-binding moieties are each an ansamycin antibiotic.
- 30. The method of claim 12, wherein the first and second hsp-binding moieties are each an ansamycin antibiotic.
  - 31. The method of claim 13, wherein the linker is a substituted carbon chain.
- 32. The method of claim 31, wherein the linker is a substituted carbon chain incorporating a secondary or tertiary amine.

ŧ.

- 33. The method of claim 32, wherein the linker is an N-methylamino linker.
- 34. The method of claim 32, wherein the first and second hsp-binding moieties are each an ansamycin antibiotic.
- 35. The method of claim 13, wherein the first and second hsp-binding moieties are each an ansamycin antibiotic.

## **REMARKS**

This is in response to the Restriction Requirement mailed August 13, 2002 in which the Examiner required an election of species. Applicants hereby elect the species wherein both the first and second hsp-binding moieties are geldanamycin and the linker is four carbons long. All of claims 1, 2, 6, 7 and 12-14 which the Examiner identified as being subject to the restriction requirement are generic with respect to the elected species.

Applicants note that the Examiner did not refer in the restriction requirement to claims 15-17 which were added in the same preliminary amendment that canceled claims 3-6 and 8-11. These claims are also generic with respect to the elected species.